Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Clene Inc. CLNN

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$200,000
▼ 41.5% YoY
$-26.2M
$-18.6M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 200,000.00
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.2 · Net income -26.2
-20M-40M
201920222025
Compound annual growth
−24.9%
−0.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −0.6% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -11541.5%
-5000%-10000%
201920222025
ROE
FY2023 · ROE -595.5%
-200%-400%
201920222025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -189%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -18.6
-20M-40M
201920222025

Total assetsUSD 18.1M
EquityUSD -17.6M
CashUSD 5.2M
Gross debtUSD 17.8M
Net debtUSD 12.6M
Current ratio0.83×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 7-year record

7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
CLNN, 7-year financial record
Metric 2025202420232022202120202019
Revenue $B0.00.00.00.00.00.0◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.0−0.00.0◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $◌◌◌◌−0.16−1.10−0.93
Dividend / sh $◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————
ROE %——−595.5−377.9−150.6——
Shares out B0.010.010.130.070.060.060.02

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 28 reconciliationsAUDITED

Reconciled in 7 of the 7 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 14 checks were skipped: cost of revenue is not tagged before 2021. 12 checks were skipped: EPS is not tagged before 2019.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2019

Share this section

Download image